Kovack Advisors’s ImmunityBio IBRX Stock Holding History

Kovack Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$162K	Buy	22,208 +8,575	+63%	+$58.7K	0.01%	951
2025 Q4	$27K	Buy	+13,633	New	+$30.9K	﹤0.01%	1005

Other funds holding IBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Kovack Advisors's IBRX Position: Q1 2026 in Review

Kovack Advisors increased its ImmunityBio (IBRX) stake by 63% in Q1 2026, buying an estimated $58.7K and bringing the position to 22,208 shares worth $162K. The position accounts for 0.01% of the portfolio, ranked #951.

Kovack Advisors first reported a position in IBRX in Q4 2025 and has held it in 2 quarters since. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

Kovack Advisors held 22,208 shares of ImmunityBio worth $162K as of Q1 2026.
Kovack Advisors bought 8,575 ImmunityBio shares in Q1 2026, an estimated $58.7K.
ImmunityBio made up 0.01% of Kovack Advisors's portfolio in Q1 2026, its #951 holding.
Kovack Advisors first reported a position in ImmunityBio in Q4 2025 and has held it in 2 quarters since.
386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Kovack Advisors's 13F filing for Q1 2026, filed 13 May 2026.